Sandostatin LAR Stungulyfsstofn og leysir, dreifa 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 10 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 10 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 20 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 20 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 30 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 30 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 30 mg

Sertralin Krka (Sertralin KRKA) Filmuhúðuð tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sertralin krka (sertralin krka) filmuhúðuð tafla 50 mg

krka sverige ab - sertralinum hýdróklóríð - filmuhúðuð tafla - 50 mg

Tamsulosin Medical (Tamsulijn) Hart hylki með breyttan losunarhraða 0,4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tamsulosin medical (tamsulijn) hart hylki með breyttan losunarhraða 0,4 mg

medical ehf. - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg

Degarelix Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Soltamcin Tafla með breyttan losunarhraða 6 mg/0,4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

soltamcin tafla með breyttan losunarhraða 6 mg/0,4 mg

williams & halls ehf. - solifenacinum súkkínat; tamsulosinum hýdróklóríð - tafla með breyttan losunarhraða - 6 mg/0,4 mg

Sorafenib Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - Æxlishemjandi lyf - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Sertral Filmuhúðuð tafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sertral filmuhúðuð tafla 50 mg

teva b.v.* - sertralinum hýdróklóríð - filmuhúðuð tafla - 50 mg

Sertral Filmuhúðuð tafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sertral filmuhúðuð tafla 100 mg

teva b.v.* - sertralinum hýdróklóríð - filmuhúðuð tafla - 100 mg